These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28761614)

  • 1. [Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014].
    Landoh DE; Kahn AL; Lacle A; Adjeoda K; Saka B; Yaya I; Nassoury DI; Kalao A; Makawa MS; Biey NJ; Bita A; Toke YT; Dörte P; Imboua L; Ronveaux O
    Pan Afr Med J; 2017; 27():38. PubMed ID: 28761614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A field based evaluation of adverse events following MenAfriVac® vaccine delivered in a controlled temperature chain (CTC) approach in Benin.
    Steffen C; Tokplonou E; Jaillard P; Dia R; Alladji MN; Gessner B
    Pan Afr Med J; 2014; 18():344. PubMed ID: 25574320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic evaluation of the controlled temperature chain approach for vaccine logistics: evidence from a study conducted during a meningitis A vaccine campaign in Togo.
    Mvundura M; Lydon P; Gueye A; Diaw IK; Landoh DE; Toi B; Kahn AL; Kristensen D
    Pan Afr Med J; 2017; 27(Suppl 3):27. PubMed ID: 29296162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin.
    Zipursky S; Djingarey MH; Lodjo JC; Olodo L; Tiendrebeogo S; Ronveaux O
    Vaccine; 2014 Mar; 32(13):1431-5. PubMed ID: 24559895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012.
    Caini S; Beck NS; Yacouba H; Maiga I; Chaibou I; Hinsa I; Adakal A; Issoufou A; Kim SH; Pezzoli L
    Vaccine; 2013 Mar; 31(12):1597-603. PubMed ID: 23337027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of the immunization coverage determinants of vaccination campaign against meningococcal A meningitis in Burkina Faso].
    Ouatara S; Faye A; Leye MM; Niang K; Tal-Dia A
    Rev Epidemiol Sante Publique; 2015 Dec; 63(6):347-53. PubMed ID: 26547670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of incomplete immunization coverage among one to five years old children in Togo.
    Landoh DE; Ouro-Kavalah F; Yaya I; Kahn AL; Wasswa P; Lacle A; Nassoury DI; Gitta SN; Soura AB
    BMC Public Health; 2016 Sep; 16(1):968. PubMed ID: 27618851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
    Karachaliou A; Conlan AJ; Preziosi MP; Trotter CL
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S594-600. PubMed ID: 26553693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.
    Trotter CL; Lingani C; Fernandez K; Cooper LV; Bita A; Tevi-Benissan C; Ronveaux O; Préziosi MP; Stuart JM
    Lancet Infect Dis; 2017 Aug; 17(8):867-872. PubMed ID: 28545721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
    White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
    Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial.
    Yang J; Acosta CJ; Si GA; Zeng J; Li CY; Liang DB; Ochiai RL; Page AL; Danovaro-Holliday MC; Zhang J; Zhou BD; Liao HZ; Wang ML; Tan DM; Tang ZZ; Gong J; Park JK; Ali M; Ivanoff B; Liang GC; Yang HH; Pang T; Xu ZY; Donner A; Galindo CM; Dong BQ; Clemens JD
    BMC Public Health; 2005 May; 5():49. PubMed ID: 15904514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2014-2019.
    Che X; Liu Y; Wang J; Xu Y; Zhang X; Gu W; Jiang W; Du J; Zhang X
    PLoS One; 2021; 16(5):e0251567. PubMed ID: 34032806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
    Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
    Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.